Filgotinib

Filgotinib
Clinical data
Trade namesJyseleca
Other namesGLPG0634, GS-6034[1]
Routes of
administration		By mouth
Drug classJanus kinase inhibitor
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)[2]
  • EU: Rx-only[3][4]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life6 hours[5]
Identifiers
  • N-[5-[4-[(1,1-Dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23N5O3S
Molar mass425.51 g·mol−1
3D model (JSmol)
  • O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
  • InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27) checkY
  • Key:RIJLVEAXPNLDTC-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA).[3] It was developed by the Belgian-Dutch biotech company Galapagos NV.[6]

The most common side effects include nausea (feeling sick), upper respiratory tract infection (nose and throat infection), urinary tract infection and dizziness.[3]

Filgotinib was approved for medical use in both the European Union and Japan in September 2020.[3][6][7]

  1. ^ "Pipeline". Gilead Sciences. 27 July 2020. Retrieved 27 July 2020.
  2. ^ "Jyseleca 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 1 October 2020. Retrieved 4 October 2020.
  3. ^ a b c d "Jyseleca EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 4 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ "Jyseleca Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  5. ^ Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.
  6. ^ a b "European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis" (Press release). Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.
  7. ^ "Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis". Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.